This handout is for priapism — urological emergency (ischemic / non-ischemic / stuttering / scd-driven / drug-induced). Your care team identified this based on: painful prolonged erection >4 h — ischemic priapism (aua 2022).
Other reasons your team may use this plan: painless partial tumescence — non-ischemic / high-flow priapism (aua 2022); known scd with vaso-occlusive crisis + priapism (ash scd 2014); recent intracavernous pge1, trazodone, antipsychotic, cocaine, methamphetamine exposure (aua 2022).
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| phenylephrine | 100–500 µg in 1 mL sterile saline intracavernous q3–5 min | intracavernous | q3–5 min PRN | AUA 2022 first-line intracavernous sympathomimetic; selective α1 agonist with minimal β effect — preferred over epinephrine; ~80% success if <12 h (intracavernous epinephrine series) |
| acetaminophen | 15 mg/kg PO/IV (max 1 g/dose adult) | PO/IV | q6h, max 4 g/day adult | Multimodal opioid-sparing (AUA 2022) |
| morphine | 0.1 mg/kg IV (typical 4–10 mg adult) | IV | q3–4h PRN | Severe ischemic pain (AUA 2022) |
Plan: Ischemic priapism — aspiration + intracavernous phenylephrine → shunt → prosthesis (AUA 2022)
Contact your care team if any of the following happen:
Call 911 or go to the nearest emergency room right away if you have:
Urology 1–2 wk; sexual function counsel + IIEF-5 at 3 / 6 / 12 mo; SCD comorbidity management + hydroxyurea optimization; psychological support if orchiectomy-equivalent ED outcome (AUA 2022; Arap-pattern outcomes)
Guideline: AUA/SMSNA Acute Ischemic Priapism Guideline 2021 (Bivalacqua, J Urol 2021 PMID 34495686) + AUA/SMSNA Recurrent Ischemic / Sickle-Cell / Non-Ischemic Priapism Guideline 2022 (Bivalacqua, J Urol 2022 PMID 35536142) + Broderick ICSM priapism review (J Sex Med 2010 PMID 20092449). Sickle-cell systemic management routes to heme.sickle-cell.core.v1.